CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

Inclusion criteria

• ✓. Patients who are at least 18 years of age.
• ✓. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
• ✓. Life expectancy of at least 12 weeks.
• ✓. Patients with potentially resectable IIIA/B (T1-3, N2) NSCLC (per the 8th International Association for the Study of Lung Cancer classification) who are candidates for surgery with intent of R0 resection. Invasive T3 disease (eg, phrenic nerve, pericardium, chest wall other than Pancoast superior sulcus) may be included if the surgeon and study team deem it to be resectable. T4 disease per AJCC 8th edition staging system is excluded given the lack of benefit of surgery in T4N2.
• ✓. Patients must be evaluated by a thoracic surgeon within 4 weeks of registration.
• ✓. Operability is defined as having adequate pulmonary, cardiac, renal, nutritional, musculoskeletal, neurologic, and cognitive capacity to undergo major pulmonary resection with acceptable morbidity and mortality.
• ✓. N2 nodes must be discrete (ie, not invading surrounding structures) and less than 3 cm in maximum diameter.
• ✓. Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).

Exclusion criteria